![]() The Cobas 5800 system and HIV-1 assay will be commercially available in Q4, the firm said. Maximilian Muenchhoff, Savathee Madurai, Allison Jo Hempenstall, Emily. The cobas® 5800 System helps by making automation, consolidation, integration and standardization more accessible than ever before. ![]() "The new system furthers our commitment to improve patient care by broadening access to high quality test results so clinicians can make the best treatment decisions for their patients," said Matt Sause, president and CEO of Roche Diagnostics North America. Roche is committed to reducing the burden of infectious diseases through effective testing, monitoring and management. 5 and the Roche CAP/CTM HIV-1 Test v2.0 in Quantification of C-Clade HIV-1 in Plasma. The broad on-demand assay menu delivers reliable results across a wide range of applications, making test consolidation easy and effective. Roche obtained the CE mark on the system last year, followed by the CE mark for tests to detect hepatitis B, hepatitis C, HIV-1, and a qualitative HIV-1/HIV-2 test, as well as assays to detect SARS-CoV-2, and a multiplex test detecting SARS-CoV-2, influenza A, and influenza B. The cobas 8800 System is designed to meet the ever-changing needs of your laboratory and your organization. The fully automated workflow is capable of running multiple assays simultaneously and includes sample transfer and preparation, amplification and detection, result determination, and delivery of results to a laboratory information system. ![]() The Cobas 5800 is a compact PCR system that can return up to 144 results in an eight-hour period enabling up to eight hours of walkaway time, Roche noted in a statement. NEW YORK – Roche announced on Tuesday that it has received premarket approval from the US Food and Drug Administration for its Cobas 5800 molecular diagnostics system and an assay to detect HIV-1.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |